Drug Formulation & Cell Therapy Lab
Research Field
Experience:
Associate Professor, Department of Pharmacy, National Cheng Kung University, 2024–present
Joint Appointment Professor, Department of Biomedical Engineering, National Cheng Kung University, 2020–present
Assistant Professor, Department of Pharmacy, National Cheng Kung University, 2019–2024
Postdoctoral Research Fellow, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego (UCSD), USA, 2017–2019
Doctoral Research Fellow, Nanomedicine Group, National Institute for Materials Science (NIMS), Japan, 2016–2017
Our lab is about the application of various drug formulations and cell therapies for treatments such as : cancer, brain, bone, lung and skin diseases.
If you are interested in formulation / biomaterials design, cell culture, and animal studies, you are most welcome to join us.
Drug Formulation Development; Drug deliver system; Immunotherapy; Cell Therapy; Gene delivery; Biomaterial carriers; Tissue Engineering
Recent Publications
1. Cheng-Li Lin, Yu-Wei Chen, Cheng-Hsiang Kuo, Ting-Yuan Tu, Hua-Lin Wu, Jui-Chen Tsai, Yan-Jye Shyong *, Calcium phosphate complex of recombinant human thrombomodulin promote bone formation in interbody fusion, Biofabrication 17 (2024) 015010. 5 year IF = 9.8, Top 9.4% in Biomedical Engineering.
2. Shang-Wen Lin, Cheng-Ping Yu, Jui-Chen Tsai, Yan-Jye Shyong *, Delivery of extracellular vesicles loaded with immune checkpoint inhibitors for immunotherapeutic management of glioma, Materials Today Bio. 28 (2024) 101244. 5 year IF = 8.8, Top 8.6% in Biomedical Engineering.
3. Cheng-Li Lin, Yu-Wen Su, Yu-Wei Chen, Cheng-Hsiang Kuo, Ting-Yuan Tu, Jui-Chen Tsai, Yan-Jye Shyong *, BMSC loaded photo-crosslinked hyaluronic acid/collagen hydrogel incorporating FG4592 for enhanced cell proliferation and nucleus pulposus differentiation, Int. J. Biol. Macromol. 273 (2024) 132828. 5 year IF = 7.7, Top 4.8% in Polymer Science.
4. Cheng-Li Lin, Yi-Lian Li, Yu-Wei Chen, Cheng-Hsiang Kuo, Ting-Yuan Tu, Yuan-Fu Liu, Jui-Chen Tsai, Yan-Jye Shyong *, Amphiphilic NLC-Gel formulation loaded with Sebacoyl dinalbuphine ester and Nalbuphine for localized postoperative pain management, Int J Pharm. 659 (2024) 124295. 5 year IF = 5.6, Top 9.5% in Pharmacology & Pharmacy.
5. Cheng-Ping Yu, Shang-Wen Lin, Jui-Chen Tsai, Yan-Jye Shyong *, Long acting tariquidar loaded stearic acid-modified hydroxyapatite enhances brain penetration and antitumor effect of temozolomide, Eur J Pharm Biopharm. 197 (2024) 114231.
6. Kuo-Yuan Huang, Yu-Wei Chen, Tzu-Yu Liang, Min-Hua Lai, Jui-Chen Tsai, Yan-Jye Shyong*, Evaluation of calcium phosphate-zoledronic acid microparticles as a localized delivery system on bone defect: An in vivo study, J. Drug Deliv. Sci. Technol. 91 (2024) 105260.
7. Chian-Wei Chen#, Chun-Ping Chang#, Yi-Shuan Wen, Cheng-Hsiang Kuo, Shang-Wen Lin, Jui-Chen Tsai, Yan-Jye Shyong*. Pulmonary delivery of remdesivir and dexamethasone encapsulated nanostructured lipid carriers for enhanced inflammatory suppression in lung. J. Drug Deliv. Sci. Technol. 90 (2023) 105144
8. Shang-Wen Lin, Tsai JC, Yan-Jye Shyong*. Drug delivery of extracellular vesicles: Preparation, delivery strategies and applications. Int J Pharm. (2023) Jul 25;642:123185.
9. Feng-Huei Lin, Yu-Chen Hsu, Kuo-Chi Chang, Yan-Jye Shyong*. Porous hydroxyapatite carrier enables localized and sustained delivery of honokiol for glioma treatment. Eur J Pharm Biopharm. (2023) Aug;189:224-232.
Ph.D., Institute of Biomedical Engineering, National Taiwan University, 2017
M.S., Institute of Biomedical Engineering, National Yang-Ming University, 2011
B.S., Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, 2006
Job Description
Nanoparticle based Gene therapy, for Dystrophic Epidermolysis Bullosa (EB).
Epidermolysis Bullosa (EB) is characterized by skin fragility, hence the disease manifests with open wounds.
- Nano-carrier for base pair editing or Collagen VII delivery
- Enhanced transfection through endosome escape and membrane penetration.
- FDA approved excipient were used for rapid approval to clinical trail.
- Much cheaper and more affordable
- Stem cell or exosomal therapy for EB treatment
- Higher novelty, higher efficacy and can be used for systemic treatment.
- Have anti-inflammatory effect, and wound healing capability.
- More expansive, requires long period for FDA approval to clinical trail.
Preferred Intern Education Level
Student with Bachelor degree and pursuing for Master degree
Student with Master degree and pursuing for PhD. degree
Skill sets or Qualities
Student with Engineering, Medical or Pharmaceutical sciences background